France has authorized the production and cultivation of cannabis for medical use as the country begins to look to develop a domestic sector.
An official decree specifying the conditions and procedures of the medical pot, published in the Official Gazette on Friday, enters into force on March 1.
France has been importing cannabis products for its pilot medical marijuana program, but the decree has been issued to “allow the creation of a sector ranging from cultivation to cannabis-based medicine for medical use in France”.
But more regulations are needed to develop a medical cannabis system.
Yann Bisiou, professor of private law and criminal sciences, pointed out the shortcomings of the decree.
“In principle, the decision to promote the therapeutic use of cannabis is very good. Unfortunately here, the device is extremely complex, with no public health reasons, and it is also legally fragile in terms of the French constitution and European law, ”explains Mugglehead.
After a detailed reading, the same causes produce the same effects, this decree # cannabis the therapy is as defective as the decree #CBD. I don’t see how he can survive an appeal before @Consell_Estat or the ECJ @olivierveran @ansm @Sante_Gouv https://t.co/K73qMbOzKn
– yann bisiou (@yannbisiou) February 18, 2022
Bisiou says the decree is as flawed as the recent decree banning the sale of CBD flowers and suggests he will not survive an appeal to the Conseil d’État, the country’s highest administrative court. Last month, that court temporarily suspended the controversial CBD ban.
Read more: French court suspends ban on selling CBD flowers
According to Newsweed, the medical cannabis decree poses an underlying risk to the organization of the medical cannabis industry because the National Agency for the Safety of Medicines and Health Products (ANSM) could refuse to develop a competitive market . In theory, the agency could choose a single industrial operator to delegate production to a limited number of producers, which could limit access to medicinal cannabis.
The ANSM has been piloting a highly regulated medical cannabis program for almost a year that continues until next March. The study includes about 3,000 patients with serious conditions such as multiple sclerosis and severe epilepsy.
Production and cultivation of cannabis for medical use in France
—ANSM (@ansm) February 18, 2022
On Thursday, the ANSM said it had set up a temporary scientific committee to define specifications around cannabis-based medicines to be produced in France.
The group consists of 11 members from different ministries, representatives of the National Research Institute for Agriculture, Food and the Environment, as well as the Order of the Council of Pharmacists.
The purpose of the commission is informative and its first meeting was set for Friday.
Although France has high cannabis consumption rates compared to other European Union countries, the implementation of a recreational program seems unlikely at this time.
Last month, the lower house of parliament rejected a bill proposing a state-controlled adult market.
Read more: The National Assembly of France rejects the cannabis legalization bill
I like Mugglehead on Facebook